Home: PCU
1|2003: A CME Audio Series and Activity
Prostate Cancer Update: A CME Audio Series and Activity
Statement of Need/Target Audience
Prostate cancer is one of the most rapidly evolving fields in
urology. Published results from clinical trials lead to the emergence
of new surgical and radiation therapy techniques and therapeutic
agents, along with changes in the indications for existing treatments.
In order to offer optimal patient care — including the option
of clinical trial participation — the practicing urologist
and radiation oncologist must be well informed of these advances.
To bridge the gap between research and patient care, Prostate Cancer
Update utilizes oneon- one discussions with leading urologic oncology
investigators. By providing access to the latest research developments
and expert perspectives, this CME program assists urologists and
radiation oncologists in the formulation of up-to-date clinical
management strategies.
Global Learning Objectives
Upon completion of this activity, participants should be able
to:
- Critically evaluate the clinical implications of emerging clinical
trial data in prostate cancer treatment
- Inform patients about the specific risks and benefits of local
and systemic therapies
- Provide individualized counseling to patients regarding the
choice and timing of endocrine therapy
- Offer patients information regarding their prognosis with and
without various therapeutic options
Issue 1, 2003 of Prostate Cancer Update consists of discussions
with four research leaders on a variety of important issues, including
the role of lymph node dissection in radical prostatectomy, selection
of endocrine therapy, defining PSA relapse, chemotherapy in metastatic
disease, and high dose brachytherapy.
Specific Learning Objectives for Issue 1
Upon completion of this activity, participants should be able to:
- Determine and implement an evaluation and management algorithm
for patients with a rising PSA after their initial therapy for
prostate cancer
- Counsel patients on the risks and benefits of antiandrogen
therapy, LHRH agonist therapy and maximum androgen blockade
- Describe the clinical implications of current research in radiation
therapy of prostate cancer, including interpretation of PSA results
Accreditation Statement
This activity has been planned and implemented in accordance with
the Essential Areas and Policies of the Accreditation Council for
Continuing Medical Education (ACCME) through the joint sponsorship
of the Postgraduate Institute for Medicine and NL Communications,
Inc. The Postgraduate Institute for Medicine is accredited by the
ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Postgraduate Institute for Medicine designates this educational
activity for a maximum of 3 category 1 credits toward the AMA Physician's
Recognition Award. Each physician should claim only credits that
he/she actually spent in the activity.
Faculty Disclosure Statements
The Postgraduate Institute for Medicine has a conflict of interest
policy that requires course faculty to disclose any real or apparent
commercial financial affiliations related to the content of their
presentations/materials. It is not assumed that these financial
interests or affiliations will have an adverse impact on faculty
presentations; they are simply noted in this supplement to fully
inform participants.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant
to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed
or suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
or dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
|
